Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Using intraoperative radiation to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with minimal side effects.

October 03, 2025

Vol.51 No.36

In Brief

Break Through Cancer launches a $15M multi-institute pediatric osteosarcoma research initiative

Break Through Cancer has launched the Defying Osteosarcoma TeamLab, an initiative that brings together more than 20 researchers from eight institutions in a coordinated, multi-year effort focused on improving pediatric osteosarcoma care.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg Kimmel Institute for Cancer Immunotherapy.

September 12, 2025

Vol.51 No.33

In Brief

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

Antonio WolffMikala EgebladAntonio C. Wolff and Mikala Egeblad were named co-directors of the Breast and Gynecologic Cancer Program at Johns Hopkins Kimmel Cancer Center.

August 08, 2025

Vol.51 No.31

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

YOU MAY BE INTERESTED IN

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Genetic “Trojan horse” selectively kills cancer cells linked to Kaposi’s sarcoma, UC Davis study shows

Break Through Cancer launches a $15M multi-institute pediatric osteosarcoma research initiative

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

Renew today!

Subscriber content

Never miss an issue!

Login